Eli Lilly revenue was $21.22 b in FY, 2016 which is a 6.3% year over year increase from the previous period.

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Revenue | 23.1 b | 19.6 b | 20 b | 21.2 b |

| (15%) | 2% | 6% | |

## Cost of goods sold | 4.9 b | 4.9 b | 5 b | 5.7 b |

## Gross profit | 18.2 b | 14.7 b | 14.9 b | 15.6 b |

| 79% | 75% | 75% | 73% |

## Pre tax profit | 5.9 b | 3 b | 2.8 b | 3.4 b |

## Income tax expense | 1.2 b | 609.8 m | 381.6 m | 636.4 m |

## Net Income | 4.7 b | 2.4 b | 2.4 b | 2.7 b |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Cash | 3.8 b | 3.9 b | 3.7 b | 4.6 b |

## Accounts Receivable | 588.4 m | 566.7 m | 558.6 m | 736.9 m |

## Inventories | 2.9 b | 2.7 b | 3.4 b | 3.6 b |

## Current Assets | 13.1 b | 12.2 b | 12.6 b | 15.1 b |

## PP&E | 8 b | 8 b | 8.1 b | 8.3 b |

## Goodwill | 1.8 b | 4 b | 4 b | |

## Total Assets | 35.2 b | 37.2 b | 35.6 b | 38.8 b |

## Accounts Payable | 1.1 b | 1.1 b | 1.3 b | 1.3 b |

## Dividends Payable | 523.5 m | 530.3 m | 539 m | 548.1 m |

## Current Liabilities | 8.9 b | 11.2 b | 8.2 b | 11 b |

## Long-term debt | 4.2 b | 5.4 b | 8 b | 8.4 b |

## Total Debt | 4.2 b | 5.4 b | 8 b | 8.4 b |

## Common Stock | 698.5 m | 694.6 m | 691.3 m | |

## Additional Paid-in Capital | 5.1 b | 5.3 b | 5.6 b | 5.6 b |

## Retained Earnings | 17 b | 16.5 b | 16 b | 16 b |

## Total Equity | 17.6 b | 15.4 b | 14.6 b | 14.1 b |

## Debt to Equity Ratio | 0.2 x | 0.3 x | 0.5 x | 0.6 x |

## Debt to Assets Ratio | 0.1 x | 0.1 x | 0.2 x | 0.2 x |

## Financial Leverage | 2 x | 2.4 x | 2.4 x | 2.8 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Net Income | 4.7 b | 2.4 b | 2.4 b | 2.7 b |

## Cash From Operating Activities | 5.7 b | 4.4 b | 2.8 b | 4.9 b |

## Purchases of PP&E | (1 b) | (1.2 b) | (1.1 b) | (1 b) |

## Cash From Investing Activities | (2.1 b) | (3.9 b) | 26.8 m | (3.1 b) |

## Short-term Borrowings | 2.7 b | (2.7 b) | 1.3 b | |

## Long-term Borrowings | (10.5 m) | (1 b) | (2 b) | (200 k) |

## Dividends Paid | (2.1 b) | (2.1 b) | (2.1 b) | (2.2 b) |

## Cash From Financing Activities | (3.8 b) | (75.1 m) | (2.9 b) | (559.8 m) |

Report incorrect company information

FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
---|---|---|---|---|

## Phase III Trials Products | 8 | 7 | 17 | 19 |

## Projects in R&D Pipeline | 57 | 57 | 65 | 66 |

- Source: Company Filings

Report incorrect company information